Drug
CAM2038 clinical trials
Also written CAM2038.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
4 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2015 | 2 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 2
Braeburn Pharmaceuticals (2) · NYU Langone Health (1) · Yale University (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses CAM2038 is read from its arms, and is right about nine times in ten.
Testing it · 4
- Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)Active, not recruitingPhase 2NYU Langone HealthNCT04464980Written as XR-BUP
- Emergency Department-Initiated Buprenorphine Validation Network TrialCompletedPhase 2Yale UniversityNCT04225598Written as CAM2038
- Phase II Pharmacokinetics Study of CAM2038CompletedPhase 2Braeburn PharmaceuticalsNCT02710526Written as CAM2038
- A Multiple Dose Opioid Challenge StudyCompletedPhase 2Braeburn PharmaceuticalsNCT02611752Written as CAM2038